ProPhase Labs, Inc. Announces Resignation of Mark Leventhal as Director
June 07, 2017 at 01:35 am IST
Share
On June 5, 2017, Mark Leventhal resigned from the board of directors of ProPhase Labs, Inc. effective immediately. Mr. Leventhal's decision to resign was not the result of any disagreements with the company regarding its operations, policies, practices or otherwise.
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
PROPHASE LABS, INC. 
